Title of article
Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure
Author/Authors
Parissis، نويسنده , , John T and Adamopoulos، نويسنده , , Stamatis and Antoniades، نويسنده , , Charalambos and Kostakis، نويسنده , , George and Rigas، نويسنده , , Antonios and Kyrzopoulos، نويسنده , , Stamos and Iliodromitis، نويسنده , , Efstathios and Kremastinos، نويسنده , , Dimitrios، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2004
Pages
4
From page
1309
To page
1312
Abstract
This randomized, placebo-controlled trial showed that levosimendan administration causes a significant reduction of circulating proinflammatory cytokine interleukin-6 and soluble apoptosis mediators, such as soluble Fas and Fas ligand in patients with decompensated heart failure. These immunomodulatory effects may lead to improvement of symptoms and echocardiographic markers of cardiac contractile performance in these patients.
Journal title
American Journal of Cardiology
Serial Year
2004
Journal title
American Journal of Cardiology
Record number
1897499
Link To Document